Acasunlimab
As of the edition of 20 October 2026, Acasunlimab is an antibody: in active development; acts on CD274 and TNFRSF9.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 6, 4 stopped early
- Disease areas
- Cancer; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 0 | 0 | 4 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merus | Lead sponsor of trials | 2019 to now |